Long-term Prognostic Value of Myeloperoxidase on Acute Coronary Syndrome: A Meta-analysis

Chen, Yongle; Zhang, Feng; Dong, Lili; Shu, Xianhong

doi:10.1016/j.arcmed.2011.07.004

Cited by 15 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MPO is an inflammation biomarker that has been shown to be independently associated with acute and chronic risk of MACEs in patients with established CVD, presenting with ACS, or undergoing diagnostic cardiac catheterization101123. Serial measurements are predictive of acute progression from ACS to a MACE in patients with negative troponin I levels24.…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies reviewed elsewhere have shown that circulating MPO levels correlate with measures of CVD severity and predict short- and long-term patient outcomes1011. Plasma MPO concentration is usually measured by enzyme-linked immunosorbent assay (ELISA)11, which is costly, time-intensive and typically uses ROS generated by immunoconjugate horseradish peroxidase (HRP) instead of directly measuring MPO-derived ROS.…”

mentioning

confidence: 99%

“…Plasma MPO concentration is usually measured by enzyme-linked immunosorbent assay (ELISA)11, which is costly, time-intensive and typically uses ROS generated by immunoconjugate horseradish peroxidase (HRP) instead of directly measuring MPO-derived ROS. Historically, attempts to measure MPO by its intrinsic activity show that this requires either immunologic purification or a chemically simple source1213.…”

mentioning

confidence: 99%

See 2 more Smart Citations

A rapid bioluminescence assay for measuring myeloperoxidase activity in human plasma

2015

View full text Add to dashboard Cite

Myeloperoxidase (MPO) is a circulating cardiovascular disease (CVD) biomarker used to estimate clinical risk and patient prognosis. Current enzyme-linked immunosorbent assays (ELISA) for MPO concentration are costly and time-intensive. Here we report a novel bioluminescence assay, designated MPO activity on a polymer surface (MAPS), for measuring MPO activity in human plasma samples using the bioluminescent substrate L-012. The method delivers a result in under an hour and is resistant to confounding effects from endogenous MPO inhibitors. In a pilot clinical study, we compared MAPS and two clinical ELISAs using 72 plasma samples from cardiac catheterization patients. Results from parallel MAPS and ELISAs were concordant within 2±11 μg l−1 MPO with similar uncertainty and reproducibility. Results between parallel MAPS and ELISA were in better agreement than those between independent ELISAs. MAPS may provide an inexpensive and rapid assay for determining MPO activity in plasma samples from patients with CVD or potentially other immune and inflammatory disorders.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

A rapid bioluminescence assay for measuring myeloperoxidase activity in human plasma

2015

View full text Add to dashboard Cite

show abstract

“…Studying 1090 patients, Baldus et al (8) concluded that MPO serum levels powerfully predict an increased risk for subsequent cardiovascular events and extend the prognostic information gained from traditional biochemical markers in patients with ACS. Chen et al (12), in their study completed with 3902 patients, showed that ACS patients with high MPO levels had a poor long-term prognosis. Sawicki et al (11) found that both MPO and cTnI values were significantly lower in non-ACS subjects than in patients with ACS (the 97.5 th percentile was the cut-off ); however, the superiority of MPO over cTnI was observed in patients with unstable angina and non-ACS subjects.…”

Section: Discussionmentioning

confidence: 99%

“…Troponin-negative ACS patients who had higher MPO concentrations on admission became troponin-positive after 6 hours (11). In a meta-analysis study involving 3902 patients, Chen Y. found that ACS patients with initially high MPO levels had a poor long-term prognosis (12).…”

Section: Introductionmentioning

confidence: 99%

Role of serum myeloperoxidase, CPK, CK-MB, and cTnI tests in early diagnosis of myocardial ischemia during ERCP

Yıldız

İnce²,

Kemik³

et al. 2014

Turk J Gastroenterol

View full text Add to dashboard Cite

Background/Aims: Some patients may experience retrosternal pain during ERCP, which may be a pioneer of a serious myocardial problem, and early diagnosis is very important for the prognosis and management. In the study, we aimed to investigate the role of serum cardiac biomarkers, such as myeloperoxidase (MPO), creatine phospokinase (CPK), creatine kinase-myocardial band (CK-MB), and cTnI, on early diagnosis of myocardial ischemia during endoscopic retrograde cholangio pancreaticograpy (ERCP) procedures. Materials and Methods: In this prospective observational study, ERCP patients were separated into ischemic cardiac (n:48) and non-ischemic (n:76) groups. Serious cardiac, kidney, and liver disease patients were excluded from the study. Changes in electrocardigrapy (ECG), blood pressure, pulse rate, oxygen saturation, and serum MPO, CPK, CK-MB, and cTnI levels were investigated before and after the ERCP. Results were evaluated statistically (p<0.05). Results: Mean age was 59.76±16.62 (55♀, 69♂). Only one patient had clinically unimportant retrosternal pain (0.8%). ST-elevation was detected in 10.4% (n:5), ST-depression in 12.5% (n:6), and negative-T in 31.3% (n:15) of ischemic patients during ERCP. Systolic and diastolic blood pressure and pulse rates in both groups and oxygen saturations in the ischemic group were reduced after ERCP. Significance was not detected with MPO and CPK tests. CK-MB levels showed an increase after the ERCP in the non-ischemic group (p<0.001). cTnI means were higher among the ischemics when pre-and post-ERCP periods (p:0.001) were compared. Conclusion: Clinically unimportant retrosternal pain, T negativity, and ST segment changes as well as reduced systolic, diastolic blood pressure, and heart rates can be seen during ERCP. MPO and CPK levels remain insignificant if myocardial injury does not develop. Increased CK-MB levels in non-ischemic patients and increased cTnI levels in ischemics may be seen.

show abstract

Sequential Analysis of Myeloperoxidase for Prediction of Adverse Events After Suspected Acute Coronary Ischemia

Koch

Henrich

Heidt³

2014

Clinical Cardiology

View full text Add to dashboard Cite

Background: Myeloperoxidase (MPO) plasma values predict major adverse cardiac events (MACE) in cases of acute coronary syndrome. The effect of serial testing in patients who are suspected for acute coronary ischemia is unclear. Hypothesis: We hypothesize that sequential MPO measurement may improve prediction of MACE in patients with suspected acute coronary ischemia. Methods: The present prospective observational study examined the prognostic significance of MPO in 917 patients with suspicion of acute coronary syndrome. Blood samples were taken at cardiac catheter laboratory admission and the day after coronary angiography. We recorded patients' mortality, the occurrence of cardiac ischemia, and repeated percutaneous coronary intervention through the next 6 months. Results: Mortality among patients with increased MPO plasma levels the day after coronary angiography was increased significantly (P < 0.01). Patients with MPO values above 306.3 pmol/L had a significantly higher incidence of 6-month MACE (P < 0.0001) than patients with lower plasma values. Cox proportional hazards multivariate regression analyses revealed that MPO was an independent marker for MACE after suspected acute coronary ischemia (P = 0.048). However, MPO plasma levels at cardiac catheter laboratory admission showed no prognostic significance. Conclusions: In patients with suspected myocardial infarction, MPO levels above 306.3 pmol/L measured 24 hours after onset of symptoms were independent predictors of 6-month mortality and MACE.

show abstract

Long-term Prognostic Value of Myeloperoxidase on Acute Coronary Syndrome: A Meta-analysis

Cited by 15 publications

References 29 publications

A rapid bioluminescence assay for measuring myeloperoxidase activity in human plasma

A rapid bioluminescence assay for measuring myeloperoxidase activity in human plasma

Role of serum myeloperoxidase, CPK, CK-MB, and cTnI tests in early diagnosis of myocardial ischemia during ERCP

Sequential Analysis of Myeloperoxidase for Prediction of Adverse Events After Suspected Acute Coronary Ischemia

Contact Info

Product

Resources

About